Merge revenues grow during second quarter
Merge revenues grow during second quarterConnectivity and PACS firm Merge Technologies reported preliminary results for its second quarter that will be below analysts’ expectations, according to the company. The Milwaukee, WI-based vendor
Merge revenues grow during second quarter
Connectivity and PACS firm Merge Technologies reported preliminary results for its second quarter that will be below analysts expectations, according to the company. The Milwaukee, WI-based vendor expects revenue to be approximately $2.8 million, a 47% increase compared with the $1.9 million reported in the same period last year. Merge anticipates a net loss of 8 cents to 11 cents a share for the quarter (end-June). The company had a net loss of 12 cents per share in the same period in 1998.
In other Merge news, the company has installed its 275th MergeWorks DICOM clinical imaging network in the U.S. Merge began shipping MergeWorks in the U.S. in 1996. Earlier this year, Merge began offering MergeWorks in Europe, and the company has installed networks at five European sites. In the second quarter, the firms systems solutions division posted a 70% increase in revenue compared with the same period in 1998.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
